{"id":33277,"date":"2025-05-23T06:55:26","date_gmt":"2025-05-23T04:55:26","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/05\/23\/cxcl14-is-an-essential-modulator-of-tlr9-agonist-induced-antitumor-immune-responses\/"},"modified":"2025-05-23T06:55:26","modified_gmt":"2025-05-23T04:55:26","slug":"cxcl14-is-an-essential-modulator-of-tlr9-agonist-induced-antitumor-immune-responses","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/05\/23\/cxcl14-is-an-essential-modulator-of-tlr9-agonist-induced-antitumor-immune-responses\/","title":{"rendered":"CXCL14 is an essential modulator of TLR9 agonist-induced antitumor immune responses"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2025 May 23:vkaf080. doi: 10.1093\/jimmun\/vkaf080. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Cancer immunotherapeutic CpG oligodeoxynucleotide (ODN) is an agonist for TLR9 and a potent inducer of inflammatory cytokines and type I interferon. Clinical trials of CpG ODNs highlight the urgent need for effective TLR9 agonist CpG ODNs in humans. Here, we developed a highly potent CpG ODN, A602, which induces antitumor immune responses in combination with CXCL14. A602 induced secretion of interferon-\u03b1 by human peripheral blood mononuclear cells. In mouse macrophages, dendritic cells, and human plasmacytoid dendritic cell lines, CXCL14 enhanced cellular uptake of A602, thereby promoting TLR9-mediated immune responses. Importantly, A602 exhibited strong antitumor activity in syngeneic mouse models of colorectal cancer-derived CT26, B lymphoma-derived A20, and melanoma-derived B16F10 cells. Because the antitumor effect of A602 against B16F10 cells was negated in Cxcl14 knockout mice, endogenously expressed CXCL14 is required for the A602-mediated tumor suppression. Thus, modulation of CXCL14 during the A602-induced immune responses shall unveil an innovative new approach for the antitumor immune therapy.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40404173\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20250523005518&amp;v=2.18.0.post9+e462414\">40404173<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkaf080\">10.1093\/jimmun\/vkaf080<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2025 May 23:vkaf080. doi: 10.1093\/jimmun\/vkaf080. Online ahead of print. ABSTRACT Cancer immunotherapeutic CpG oligodeoxynucleotide (ODN) is an agonist for TLR9 and a potent inducer of inflammatory cytokines and type I interferon. Clinical trials of CpG ODNs highlight the urgent need for effective TLR9 agonist CpG ODNs in humans. Here, we developed a highly &#8230; <a title=\"CXCL14 is an essential modulator of TLR9 agonist-induced antitumor immune responses\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/05\/23\/cxcl14-is-an-essential-modulator-of-tlr9-agonist-induced-antitumor-immune-responses\/\" aria-label=\"Read more about CXCL14 is an essential modulator of TLR9 agonist-induced antitumor immune responses\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-33277","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/33277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=33277"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/33277\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=33277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=33277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=33277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}